Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Celsius Holdings, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Celsius Holdings, Inc. trades at $30.53 (market cap $8.10B). The key difference: Celsius Holdings, Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | CELH | |
|---|---|---|
Market Cap | $4.49B | $8.10B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $64.86 |
52-Week Low | $20.06 | $27.75 |
Enterprise Value | $3.69B | $9.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Celsius Holdings (CELH) trades at $31.70, down 4.4% on the day, with strong analyst consensus (95.65% buy ratings) and a $53.11 price target. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.41 beating expectations of $0.29. Revenue growth is robust, projected at $3.0B for 2026, though net margins have compressed from 17.2% in 2023 to 4.29% in 2025. Technical indicators show a bullish moving average trend but neutral oscillators, with key resistance at $34.
The outlook remains positive driven by international expansion and functional beverage demand, but risks include margin pressure, ongoing legal investigations, and high valuation multiples. The stock offers significant upside to consensus targets if growth execution continues, though investor sentiment is tempered by near-term profitability concerns and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
